In a revolutionary clinical trial, the first trial on psilocybin for the treatment of depression Type II bipolar treatment has shown promising results. The test, led to Sheppard Pratt and published in Jama Psychiatry, explores the efficiency and safety of a single dose of synthetic psilocybin accompanied by psychotherapy in the treatment of people with type II bipolar disorder resistant to treatments. The test results are encouraging, with 80% of participants meeting the criteria for remission 12 weeks after treatment.
The study on psilocybin for bipolar depression
The 12 -week open test was initiated and led by Scott T. Aaronson, scientific director of the Institute for diagnostics and advanced therapies in Sheppard Pratt. The study understood 15 participants aged 18 to 65 affected type II bipolar disorder resistant to treatments. Each participant had experienced an episode of type II bipolar disorder for a period of more than three months and had documented at least two unsuccessful pharmacological treatments during the current episode.
Psilocybin treatment protocol
Test participants have:
-
Order Psychotropic drugs at least two weeks before
-
Received a Only dose of comp360 synthetic psilocybin (25 mg) in a controlled framework.
- THE therapists held sessions with patients at length of the day.
-
Three sessions were carried out Before the start of the test, and three integration sessions took place after treatment.
- THE funding study will allow also to watch THE results patients during two years after treatment.
Encouraging results on taking psilocybin
THE results trial are very encouraging:
- A participant described the transformation she experienced as taking a deep inspiration after breathing through a straw for years.
- Many people who have fought against bipolar disorder type II for years and had lost all hope of treatment reported similar stories.
- In this small pilot study, No patient has developed psychotic symptoms during treatment, and 73% of participants have replied to criteria of remission According to Montgomery Asberg's depression scale three weeks after treatment.
Long -term remission on psilocybine treatment for bipolar treatment
Even more remarkable, 80% of participants have known a remission without increased symptoms of disorder bipolar type II such that the mania, Hypomania or the suicidability Twelve weeks after treatment. These results suggest not only the effectiveness of the psilocybin In the treatment of type II bipolar depression, but also its safety. It is important to note that the results of this study cannot be extrapolated to studying psilocybin in the treatment of type I bipolar disorder.
Conclusion
The first test on psilocybin for the treatment of bipolar depression of type II resistant treatments has given promising results. With 80% of participants meeting the criteria for remission 12 weeks after treatment, this study revolutionary Indicates the potential of the psilocybin in the treatment of depression bipolar type II. Although additional research is necessary, these results give hope to people who have fought against this disorder for years. Psilocybin could offer an effective new processing route and improve the quality of life of people with type II -resistant bipolar disorder.
Faq
1. What is the importance of this essay on psilocybin for bipolar depression?
- This trial is the first of its kind and has shown promising results in the treatment of type II bipolar disorder resistant to treatments.
2. How many participants were included in the study?
- The study included 15 participants aged 18 to 65 with type II -resistant bipolar disorder.
3. What were the selection criteria for participants?
- Participants must have experienced an episode of type II bipolar disorder for a period of more than three months and having documented at least two unsuccessful pharmacological treatments during the current episode.
4. What was the dosage of the psilocybin administered to the participants?
- Participants received a single dose of comp360 synthetic psilocybin (25 mg) in a controlled frame.
5. What were the test results?
- 80% of participants met the criteria for remission 12 weeks after treatment, without increasing symptoms of type II bipolar disorder.
6. Have some participants developed psychotic symptoms during treatment?
- No observation indicates that patients have developed psychotic symptoms during treatment.
7. For how long have participants been monitored after treatment?
- The financing of the study made it possible to monitor patient results for two years after treatment.
8. Can the results of this study apply to type I bipolar disorder?
- The results of this study suggest the efficiency and safety of psilocybin in the treatment of type II bipolar depression, but cannot be extrapolated to studying psilocybin in the treatment of type I bipolar disorder.
9. What did a participant compared her experience?
- A participant compared the transformation she experienced to a deep inspiration after breathing through a straw for years.
10. What is the next step after this test?
- Additional research is necessary to explore the potential of psilocybin in the treatment of type II bipolar depression and expand the scope of its use in the treatment of mental health disorders.
Disclaimer/Important opinion
This study on the use of psilocybin in the treatment of type II bipolar depression offers promising results that arouse significant interest. However, it is imperative to emphasize that the use of psilocybin is currently prohibited in most countries. The results of this research do not justify the self-administration of psilocybin or similar substances.
It is strongly recommended to consult a health professional before undertaking any treatment involving psychoactive substances. Medical authorization and supervision are essential to guarantee the safety and efficiency of treatment.
The information provided in this study is intended for informative and research purposes only. They should in no case replace advice, diagnostics or professional medical treatments. People interested in innovative treatments, such as those involving psilocybin, must participate in clinical studies under the supervision of qualified health professionals.
